학술논문
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
Document Type
article
Author
Marjan M. Naeini; Felicity Newell; Lauren G. Aoude; Vanessa F. Bonazzi; Kalpana Patel; Guy Lampe; Lambros T. Koufariotis; Vanessa Lakis; Venkateswar Addala; Olga Kondrashova; Rebecca L. Johnston; Sowmya Sharma; Sandra Brosda; Oliver Holmes; Conrad Leonard; Scott Wood; Qinying Xu; Janine Thomas; Euan Walpole; G. Tao Mai; Stephen P. Ackland; Jarad Martin; Matthew Burge; Robert Finch; Christos S. Karapetis; Jenny Shannon; Louise Nott; Robert Bohmer; Kate Wilson; Elizabeth Barnes; John R. Zalcberg; B. Mark Smithers; John Simes; Timothy Price; Val Gebski; Katia Nones; David I. Watson; John V. Pearson; Andrew P. Barbour; Nicola Waddell
Source
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Subject
Language
English
ISSN
2041-1723
Abstract
Abstract Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients mostly from the DOCTOR phase II clinical trial (Australian New Zealand Clinical Trials Registry-ACTRN12609000665235), with exploratory analysis pre-specified in the study protocol of the trial. We report genomic features associated with poorer overall survival, such as the APOBEC mutational and RS3-like rearrangement signatures. We also show that positron emission tomography non-responders have more sub-clonal genomic copy number alterations. Transcriptomic analysis categorises patients into four immune clusters correlated with survival. The immune suppressed cluster is associated with worse survival, enriched with myeloid-derived cells, and an epithelial-mesenchymal transition signature. The immune hot cluster is associated with better survival, enriched with lymphocytes, myeloid-derived cells, and an immune signature including CCL5, CD8A, and NKG7. The immune clusters highlight patients who may respond to immunotherapy and thus may guide future clinical trials.